Meet Lumara: A New Contender in Severe AsthmaIn Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market. With launch roughly 12 months out, early conversations with payers and providers have begun, and the competitive set—Dupixent, Fasenra, Tezspire, Nucala—is well established. We frame the stakes, surface emerging access vulnerabilities, and set the tone for an eight-part, intelligence-driven series built for time-constrained market access and brand leaders.What you’ll learnThe current access landscape for specialty meds in severe asthmaTypical launch challenges for new entrants in entrenched TAsWhy Lumara represents a realistic, high-stakes competitorThe competitive-intelligence themes we’ll unpack across the seriesFeatured segmentsThree Strategic Questions Every Entrant Must AnswerWhat the Market Looks Like Today — quick stats and payer trendsIn the Shoes of a Payer — early positioning challenges for LumaraAbout the series & how it was made The Lumara Series is both an educational flyover of biologic commercialization and a live demo of what consumer-grade GenAI tools can produce—fast and affordably. Imperfections aside, the direction is transformative. Genflare acts as your CI partner, connecting dots and translating signals into action.

Ver todos los episodios